Cost–Benefit Analysis for Synthetic Nucleic Acid Screening in the European Union

Why It Matters

The analysis provides policymakers quantitative evidence that stronger screening can dramatically improve biosecurity without stifling innovation, guiding proportionate EU regulation. Spillover effects also suggest global risk reduction beyond EU borders.

Key Takeaways

• Mandatory screening yields €4.6B annual benefit
• Voluntary guidance provides €193M yearly gain
• Funding conditionality improves benefits to €1.1B annually
• EU harmonisation prevents market fragmentation and arbitrage
• Design minimizes SME burden, ensures compliance efficiency

Pulse Analysis

Synthetic DNA and RNA are now routine inputs for vaccines, diagnostics, therapeutics and industrial biotech, but the same ordering infrastructure can be misused to obtain sequences with hazardous functions. As the technology becomes cheaper and faster, governments worldwide are grappling with how to balance open scientific collaboration against the risk of accidental or deliberate misuse. The EU’s unique market structure, with 27 member states and a single internal market, makes a coordinated approach essential to avoid regulatory gaps that could be exploited by malicious actors.

The RAND Europe study models three policy pathways over a decade, quantifying both the security gains and the economic costs. Voluntary guidance delivers modest annual benefits of €193 million, while linking screening compliance to EU research funding raises the upside to €1.1 billion per year. A mandatory EU‑wide regime generates the highest net benefit—€4.6 billion annually—equating to six euros of avoided loss for every euro spent. Crucially, the analysis shows that harmonised rules prevent market fragmentation, protect responsible providers from competitive disadvantages, and limit order diversion to jurisdictions with weaker safeguards. Thoughtful implementation, such as phased roll‑outs and SME‑friendly procedures, can further minimise administrative burdens.

Beyond the EU, the study highlights a significant international spillover: suppliers operating globally may adopt EU‑level standards, amplifying risk reduction by roughly 50 percent without proportionate cost increases. This creates a compelling case for the EU to set a regulatory precedent that other regions emulate. For industry leaders, the findings suggest that investing in robust screening infrastructure now can safeguard research continuity while contributing to a safer global biotech ecosystem. Policymakers can leverage these insights to craft proportionate, evidence‑based regulations that strengthen biosecurity without hampering innovation.